The Gluco Track Blood Glucose Monitoring System is intended for the quantitative measurement of glucose in fresh capillary, fingerstick whole blood. Testing is done outside the body (in vitro diagnostic use). It is indicated for both lay use by people with diabetes and in a clinical setting by health care professionals, as an aid to monitoring levels in Diabetes Mellitus.

Device Description

Based on an electrochemical biosensor technology and the principle of capillary action, Gluco Track Blood Glucose Monitoring System only needs a small amount of blood. Capillary action at the end of the test strip draws the blood into the action chamber and your blood glucose result is precisely and displayed in 6 seconds.

AI/ML Overview

This document does not provide enough information to construct the requested table and complete all sections of the study description. The provided text is a 510(k) summary for a blood glucose monitoring system, which primarily focuses on establishing substantial equivalence to a predicate device rather than detailing specific performance studies with acceptance criteria and ground truth.

Here's what can be extracted and what information is missing:

1. Table of Acceptance Criteria and Reported Device Performance

Acceptance Criteria	Reported Device Performance
Not specified in the provided text.	Not specified in the provided text.

2. Sample size used for the test set and the data provenance

Sample Size: Not specified.
Data Provenance: The document states "Pre-clinical and clinical data are employed upon submission of this 510(K) premarket notification," but does not provide details on the origin (e.g., country) or whether it was retrospective or prospective.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

This information is not provided.

4. Adjudication method for the test set

This information is not provided.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done

No, an MRMC study is not mentioned as this device is a blood glucose monitoring system, not an imaging or diagnostic AI requiring human reader interaction in that context. The "clinical data" mentioned would likely be compared against a laboratory reference method, not human interpretation.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

This device is a standalone algorithm/device for measuring glucose. There isn't a "human-in-the-loop" component in the way AI in imaging is typically discussed. Its performance would inherently be "standalone." However, specific performance metrics against a defined (presumably laboratory-based) ground truth are not provided in this document.

7. The type of ground truth used

While not explicitly stated for the "clinical data," for blood glucose monitoring systems, the ground truth is typically established by laboratory reference methods (e.g., YSI or hexokinase methods) performed on venous blood samples. The device's results (from capillary blood) are then compared against these reference values.

8. The sample size for the training set

Not specified. The document does not explicitly mention a "training set" in the context of machine learning, but rather "pre-clinical and clinical data" which would be used to validate the device.

9. How the ground truth for the training set was established

Not specified. Based on the nature of the device, the ground truth for any data used in development and validation would be established by laboratory reference methods for glucose measurement.

Summary

{0}------------------------------------------------

APEX BIOTECHNOLOGY CORP

Ka62799

No. 7, Li-Shin Rd. V, Hsinchu Science Park, Hsinchu, Taiwan, ROC TEL: 886-3-5641952 FAX: 886-3-5678302

FEB -6 2007

510(K) Summary of Safety and Effectiveness II.

(Per 21 CFR 807.92)

2.1. General Information Establishment
	Manufacturer:	APEX Biotechnology Corp.
	Address:	No. 7, Li-Shin Rd. V, Hsinchu Science Park, Hsinchu, 30078, Taiwan, ROC
	Registration Number:	9616936
	Contact Person:	Dr. Jen, Ke-Min E-mail: ceirs.jen@msa.hint.net
		886-3-5208829 (Tel); 886-3-5209783 (Fax)
	Address:	No.58, Fu Chiun Street, Hsin Chu City, 30067, Taiwan, ROC
	Date Prepared:	September 15, 2006
Device
●	Proprietary Name:	Gluco Track® Blood Glucose Monitoring System
●	Common Name:	Blood Glucose Monitoring System
●	Classification Name:	SYSTEM, TEST, BLOOD GLUCOSE,
		OVER THE COUNTER, Class II,

2.2. Safety and Effectiveness Information

Predicate Device:
Claim of Substantial Equivalence (SE) is made to GlucoSure Blood Glucose Monitoring System (K011233)
Device Description: Based on an electrochemical biosensor technology and the principle of capillary action, Gluco Track Blood Glucose Monitoring System only needs a small amount of blood. Capillary action at the end of the test strip draws the blood into the action chamber and your blood glucose result is precisely and displayed in 6 seconds.
3

{1}------------------------------------------------

X BIOTECHNOLOGY CORP

No. 7, Li-Shin Rd. V, Hsinchu Science Park, Hsinchu, Taiwan, ROC TEL: 886-3-5641952 FAX: 886-3-5678302

Intended Use: .

● Synopsis of Test Methods and Results

Pre-clinical and clinical data are employed upon submission of this 510(K) premarket notification according to the Guidance Document for In Vitro Diagnostic Test System; Guidance for Industry and FDA document provided by CDRH/ FDA.

. Substantial Equivalence (SE)

A claim of substantial equivalence is made to GlucoSure Blood Glucose Monitoring System (K011233). Both of them have the same working principle and technologies. The differences are meter dimension, weight, power voltage, memory data number, date and time setting, auto recall the 7, 14 and 30 days average and some other user friendly designs on meter. As we can see, the differences are due to the feature design aspects, not relating to the safety or effectiveness aspects. They are substantially equivalent.

Ke. 22222

Dr. Jen, Ke-Min 510k Contact Person for APEX BIOTECHNOLOGY CORP.

{2}------------------------------------------------

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES. USA" around the perimeter. Inside the circle is an emblem featuring a stylized eagle or bird-like figure with outstretched wings.

Public Health Service

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Ke-Min Jen Apex Biotechnology Corp. No. 58, Fu Chium Street Hsin Chu City, 30067 Taiwan, R.O.C.

FEB - 6 2007

Re: K062799 Trade/Device Name: Gluco Track Blood Glucose Monitoring System Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system Regulatory Class: Class II Product Code: NBW, CGA, JJX Dated: January 28, 2007 Received: January 30, 2007

Dear Dr. Jen:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

{3}------------------------------------------------

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0490. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address at http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Jean M. Cooper, M.S., D.V.M.

Yean M. Cooper, M.S., D.V.M. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Indications for Use

510 (K) Number ( If Known ):____ K062799

Device Name: Gluco Track Blood Glucose Monitoring System

Indications for Use:

The Gluco Track Blood Glucose Monitoring System is intended for the quantitative measurement of glucose in fresh capillary, fingerstick whole blood. Testing is done outside the body ( in vitro diagnostic use). It is indicated for both lay use by people with diabetes and in a clinical setting by health care professionals, as an aid to monitoring levels in Diabetes Mellitus.

Prescription Use

AND/OR

Over-The-Counter Use √

(Part 21 CFR 801 Subpart D)

(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Carol Benson
Vision Sign-Off

fifice of In Vitro Diagnostic Device baluation and Safety

Page 1 of 1

K062799

Regulation Number and Section

§ 862.1345 Glucose test system.

(a)
Identification. A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.(b)
Classification. Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.